SCM
VIRX

Sio Capital Management’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Sio Capital Management’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-963
Closed -$65K – 65
2017
Q3 		$65K Hold
963
– – 0.03% 54
2017
Q2 		$91K Sell
963
-7,949
-89% -$913K 0.04% 58
2017
Q1 		$1.28M Buy
+8,912
New +$1.27M 0.72% 33

Other funds holding VIRX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Sio Capital Management's VIRX Position: Q4 2017 in Review

Sio Capital Management sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q4 2017, closing a stake of 963 shares — an estimated $65K sold.

Sio Capital Management first reported a position in VIRX in Q1 2017 and held it in 3 quarters. The position peaked at $1.28M in Q1 2017. 39 funds tracked by Wall St. Rank hold VIRX as of Q4 2017.

  • Sio Capital Management reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
  • Sio Capital Management sold 963 Viracta Therapeutics, Inc. Common Stock shares in Q4 2017, an estimated $65K.
  • Sio Capital Management first reported a position in Viracta Therapeutics, Inc. Common Stock in Q1 2017 and held it in 3 quarters.
  • Sio Capital Management's Viracta Therapeutics, Inc. Common Stock position peaked at $1.28M in Q1 2017.
  • 39 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q4 2017.

Based on Sio Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.